US$ 21.93
glp-1 agonist clinical trials GLP1 agonists: current and future landscape of for patients with metabolic dysfunction Sometimes innovation comes before the
Description
Two-Year Effects of Semaglutide in Adults with Overweight or Obesity: the STEP 5 Trial
Horowitz M, Harding PE, Maddox AF, et al

The insulin-like effect and inhibition of ACC benefit most patients with MASLD
Given MSAs rapid progression, careful patient selection and well-powered trial design will be essential to detect potential disease-modifying effects
